1 Hindle, J. V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 39, 156-161, doi:10.1093/ageing/afp223 (2010).
2 de Lau, L. M. & Breteler, M. M. Epidemiology of Parkinson's disease. Lancet Neurol 5, 525-535, doi:10.1016/S1474-4422(06)70471-9 (2006).
3 Rascol, O., Lozano, A., Stern, M. & Poewe, W. Milestones in Parkinson's disease therapeutics. Mov Disord 26, 1072-1082, doi:10.1002/mds.23714 (2011).
4 Hely, M. A. et al. Age at onset: The major determinant of outcome in Parkinson's disease. Acta Neurol Scand 92, 455-463 (1995).
5 Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427-442, doi:10.1212/wnl.17.5.427 (1967).
6 Pagano, G., Ferrara, N., Brooks, D. J. & Pavese, N. Age at onset and Parkinson disease phenotype. Neurology 86, 1400-1407, doi:10.1212/Wnl.0000000000002461 (2016).
7 Wickremaratchi, M. M. et al. The Motor Phenotype of Parkinson's Disease in Relation to Age at Onset. Movement Disord 26, 457-463, doi:10.1002/mds.23469 (2011).
8 Diamond, S., Markham, C., Hoehn, M., McDowell, F. & Muenter, M. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 39, 1187-1187 (1989).
9 Levy, G. The relationship of Parkinson disease with aging. Arch Neurol-Chicago 64, 1242-1246, doi:DOI 10.1001/archneur.64.9.1242 (2007).
10 Parkinson's Measurement Levodopa Equivalent Dose Calculator, <https://www.parkinsonsmeasurement.org/toolBox/levodopaEquivalentDose.htm> (
11 Martinez-Martin, P. et al. Global versus factor-related impression of severity in Parkinson's disease: a new clinimetric index (CISI-PD). Mov Disord 21, 208-214, doi:10.1002/mds.20697 (2006).
12 Jankovic, J. et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40, 1529-1534, doi:10.1212/wnl.40.10.1529 (1990).
13 Chaudhuri, K. R. et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 21, 916-923, doi:10.1002/mds.20844 (2006).
14 Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychology and Health 12, 805-814 (1997).
15 EuroQol, G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 16, 199-208, doi:10.1016/0168-8510(90)90421-9 (1990).
16 Team, R. C. R: A language and environment for statistical computing. . (2020).
17 Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. arXiv preprint arXiv:1406.5823 (2014).
18 Marras, C. & Lang, A. Parkinson's disease subtypes: lost in translation? Journal of Neurology, Neurosurgery & Psychiatry 84, 409-415 (2013).
19 Sokol, L. L. et al. Advance care planning in Parkinson’s disease: ethical challenges and future directions. npj Parkinson's Disease 5, 1-7 (2019).
20 Jordan, S. R. et al. Optimizing future planning in Parkinson disease: suggestions for a comprehensive roadmap from patients and care partners. Annals of palliative medicine 9, S63 (2020).
21 Schrag, A. Quality of life and depression in Parkinson's disease. Journal of the neurological sciences 248, 151-157 (2006).
22 Karlsen, K. H., Tandberg, E., Årsland, D. & Larsen, J. P. Health related quality of life in Parkinson's disease: a prospective longitudinal study. Journal of Neurology, Neurosurgery & Psychiatry 69, 584-589 (2000).
23 Goetz, C. G. et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): process, format, and clinimetric testing plan. Movement disorders 22, 41-47 (2007).
24 Chaudhuri, K. R. et al. The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: results from an international pilot study. Movement disorders 22, 1901-1911 (2007).